Last reviewed 2026-04-20 · How we verify

Eudormil (FENADIAZOLE)

Phase 2 active Small molecule

Eudormil (generic name: FENADIAZOLE) is a fenadiazole drug. It is currently in Phase 2 development.

Eudormil is thought to work by interacting with a specific target in the body, although its exact mechanism of action is currently unknown.

Eudormil, also known as Fenadiazole, is a small molecule drug in the fenadiazole class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its commercial status, pharmacokinetics, or safety profile. Further research is needed to fully understand the properties and potential uses of Eudormil. Due to its lack of FDA approval and limited information, Eudormil is not a widely recognized or established medication.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FENADIAZOLE
Drug class	fenadiazole
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Eudormil is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock and the key's shape. This can help regulate various bodily functions, but more research is needed to understand exactly how Eudormil works and what effects it has on the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Eudormil CI brief — competitive landscape report
Eudormil updates RSS · CI watch RSS

Frequently asked questions about Eudormil

What is Eudormil?

Eudormil (FENADIAZOLE) is a fenadiazole drug.

How does Eudormil work?

Eudormil is thought to work by interacting with a specific target in the body, although its exact mechanism of action is currently unknown.

What is the generic name of Eudormil?

FENADIAZOLE is the generic (nonproprietary) name of Eudormil.

What drug class is Eudormil in?

Eudormil belongs to the fenadiazole class. See all fenadiazole drugs at /class/fenadiazole.

What development phase is Eudormil in?

Eudormil is in Phase 2.

Drug class: All fenadiazole drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing